146 related articles for article (PubMed ID: 32272615)
1. Lack of Correlation between In Vitro and In Vivo Studies on the Inhibitory Effects of (‒)-Sophoranone on CYP2C9 is Attributable to Low Oral Absorption and Extensive Plasma Protein Binding of (‒)-Sophoranone.
Zheng YF; Bae SH; Huang Z; Chae SU; Jo SJ; Shim HJ; Lee CB; Kim D; Yoo H; Bae SK
Pharmaceutics; 2020 Apr; 12(4):. PubMed ID: 32272615
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic properties of trifolirhizin, (-)-maackiain, (-)-sophoranone and 2-(2,4-dihydroxyphenyl)-5,6-methylenedioxybenzofuran after intravenous and oral administration of Sophora tonkinensis extract in rats.
Jang SM; Bae SH; Choi WK; Park JB; Kim D; Min JS; Yoo H; Kang M; Ryu KH; Bae SK
Xenobiotica; 2015; 45(12):1092-104. PubMed ID: 26068519
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of cytochrome P450 2D6 by Sarpogrelate and its active metabolite, M-1, in human liver microsomes.
Cho DY; Bae SH; Lee JK; Kim YW; Kim BT; Bae SK
Drug Metab Dispos; 2014 Jan; 42(1):33-9. PubMed ID: 24167220
[TBL] [Abstract][Full Text] [Related]
4. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro.
Yasar U; Eliasson E; Forslund-Bergengren C; Tybring G; Gadd M; Sjöqvist F; Dahl ML
Eur J Clin Pharmacol; 2001 Dec; 57(10):729-35. PubMed ID: 11829203
[TBL] [Abstract][Full Text] [Related]
5. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
Bae SH; Kwon MJ; Choi EJ; Zheng YF; Yoon KD; Liu KH; Bae SK
Chem Biol Interact; 2013 Sep; 205(1):11-9. PubMed ID: 23777987
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory Effects of Dimethyllirioresinol, Epimagnolin A, Eudesmin, Fargesin, and Magnolin on Cytochrome P450 Enzyme Activities in Human Liver Microsomes.
Kim JH; Kwon SS; Jeong HU; Lee HS
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28468305
[TBL] [Abstract][Full Text] [Related]
7. Strong and Selective Inhibitory Effects of the Biflavonoid Selamariscina A against CYP2C8 and CYP2C9 Enzyme Activities in Human Liver Microsomes.
Park SY; Nguyen PH; Kim G; Jang SN; Lee GH; Phuc NM; Wu Z; Liu KH
Pharmaceutics; 2020 Apr; 12(4):. PubMed ID: 32290339
[TBL] [Abstract][Full Text] [Related]
8. In vitro inhibition of CYP2C9-mediated warfarin 7-hydroxylation by iguratimod: possible mechanism of iguratimod-warfarin interaction.
Yamaori S; Takami K; Shiozawa A; Sakuyama K; Matsuzawa N; Ohmori S
Biol Pharm Bull; 2015; 38(3):441-7. PubMed ID: 25757926
[TBL] [Abstract][Full Text] [Related]
9. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.
Wester MR; Lasker JM; Johnson EF; Raucy JL
Drug Metab Dispos; 2000 Mar; 28(3):354-9. PubMed ID: 10681382
[TBL] [Abstract][Full Text] [Related]
10. Atipamezole is a promising non-discriminative inhibitor against pan-CYP450 including diclofenac 4'-hydroxylation: A comparison with ABT for drug ADME optimization and mechanism study.
Li Z; Zhang Y; Gao Y; Xiang Y; Zhang W; Lu C; Zhuang X
Eur J Pharm Sci; 2019 Mar; 130():156-165. PubMed ID: 30690186
[TBL] [Abstract][Full Text] [Related]
11. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes.
Bourrié M; Meunier V; Berger Y; Fabre G
Drug Metab Dispos; 1999 Feb; 27(2):288-96. PubMed ID: 9929518
[TBL] [Abstract][Full Text] [Related]
12. Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti-inflammatory drug, and its lack of clinically significant CYP inhibition potential.
Furuta S; Akagawa N; Kamada E; Hiyama A; Kawabata Y; Kowata N; Inaba A; Matthews A; Hall M; Kurimoto T
Br J Clin Pharmacol; 2002 Sep; 54(3):295-303. PubMed ID: 12236850
[TBL] [Abstract][Full Text] [Related]
13. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.
Tang C; Shou M; Mei Q; Rushmore TH; Rodrigues AD
J Pharmacol Exp Ther; 2000 May; 293(2):453-9. PubMed ID: 10773015
[TBL] [Abstract][Full Text] [Related]
14. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone.
Yamazaki H; Suzuki M; Tane K; Shimada N; Nakajima M; Yokoi T
Xenobiotica; 2000 Jan; 30(1):61-70. PubMed ID: 10659951
[TBL] [Abstract][Full Text] [Related]
15. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways.
Bort R; Macé K; Boobis A; Gómez-Lechón MJ; Pfeifer A; Castell J
Biochem Pharmacol; 1999 Sep; 58(5):787-96. PubMed ID: 10449188
[TBL] [Abstract][Full Text] [Related]
16. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
Gentile DM; Verhoeven CH; Shimada T; Back DJ
J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282
[TBL] [Abstract][Full Text] [Related]
17. Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes.
Nakashima A; Kawashita H; Masuda N; Saxer C; Niina M; Nagae Y; Iwasaki K
Xenobiotica; 2005 Jun; 35(6):589-602. PubMed ID: 16192110
[TBL] [Abstract][Full Text] [Related]
18. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists.
Taavitsainen P; Kiukaanniemi K; Pelkonen O
Eur J Clin Pharmacol; 2000 May; 56(2):135-40. PubMed ID: 10877007
[TBL] [Abstract][Full Text] [Related]
19. Drug-drug interaction of losartan and glimepiride metabolism by recombinant microsome CYP2C9*1, 2C9*3, 2C9*13, and 2C9*16 in vitro.
Chen SZ; Pan PP; Shen LB; Xu SS; Dai DP; Geng PW; Cai J; Cai JP; Hu GX
Int J Clin Pharmacol Ther; 2014 Sep; 52(9):732-8. PubMed ID: 24986093
[TBL] [Abstract][Full Text] [Related]
20. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]